AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7472292 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexigenic drugs (mazindol)
Number of subjects: 4
Study 7472292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30249203 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (includes educational components, SMBP, and self-titration of antihypertensive medication)
Number of subjects: 0
Study 30249203 — intervention group
Group type: COMPARATOR
Intervention: Usual care (includes educational components)
Number of subjects: 0
Study 27481309 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 130
Study 27481309 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 350 mg
Number of subjects: 130
Study 27481309 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 700 mg
Number of subjects: 130
Study 27481309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 26769445 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Cognitive Behavioural Therapy (CBT‐E)
Number of subjects: 64
Study 26769445 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley Anorexia Nervosa Treatment for Adults (MANTRA)
Number of subjects: 64
Study 26769445 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 64
Study 23846733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,000 mg twice daily for 16 weeks)
Number of subjects: 148
Study 23846733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 23846733 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 148
Study 21120259 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical keratolytic treatment
Number of subjects: 0
Study 21120259 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 18446414 — intervention group
Group type: EXPERIMENTAL
Intervention: Online tutorial covering 2 American Diabetes Association guidelines
Number of subjects: 91
Study 15963095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine, 25 mg twice daily for 6 days
Number of subjects: 18
Study 15963095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12732397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ethinyl estradiol
Number of subjects: 30
Study 12732397 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol
Number of subjects: 30
Study 12732397 — intervention group
Group type: COMPARATOR
Intervention: Cyproterone acetate (CA)
Number of subjects: 30
Study 10484952 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study 7549168 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac 30 mg
Number of subjects: 69
Study 7549168 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 50 micrograms
Number of subjects: 69
Study 1834765 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (SCOP)
Number of subjects: 0
Study 1834765 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose Lorazepam (LOR)
Number of subjects: 0
Study 1834765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1834765 — intervention group
Group type: EXPERIMENTAL
Intervention: Neither drug (LOR or SCOP)
Number of subjects: 0
Study 7296105 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional session on hearing tactics
Number of subjects: 0
Study 7296105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not instructed)
Number of subjects: 0
Study 31625806 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 698
Study 30407275 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention led by parents (4 days/week for 24 weeks) including warm-up exercises, strengthening exercises, playground games, and interactive console games.
Number of subjects: 111
Study 30407275 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical activity intervention led by parents
Number of subjects: 111
Study 30407275 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 111
Study 28403187 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement of portable obstetric ultrasound by radio and word of mouth
Number of subjects: 159
Study 28403187 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who had previously seen a traditional healer
Number of subjects: 159
Study 28403187 — intervention group
Group type: COMPARATOR
Intervention: Control arm with advertisement of antenatal care without mention of portable obstetric ultrasound
Number of subjects: 159
Study 26551647 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen and alginate dressing (group A)
Number of subjects: 40
Study 26551647 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing alone (group B)
Number of subjects: 40
Study 23842585 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0
Study 23842585 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic normothermia
Number of subjects: 0
Study 20692141 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing method
Number of subjects: 37
Study 20692141 — intervention group
Group type: COMPARATOR
Intervention: Dosimeter method
Number of subjects: 37
Study 18722088 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture-mark-recapture (CMR; Horizon Estimate) statistical modeling
Number of subjects: 1246
Study 18722088 — intervention group
Group type: COMPARATOR
Intervention: Four large bibliographic databases (Medline, EMBASE, CINAHL, and EBM reviews)
Number of subjects: 1246
Study 17584562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 10 mg
Number of subjects: 2061
Study 17584562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg (medium dose)
Number of subjects: 2061
Study 17584562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol low dose (1.25 or 2.5 mg)
Number of subjects: 2061
Study 17584562 — intervention group
Group type: COMPARATOR
Intervention: No nebivolol (placebo)
Number of subjects: 2061
Study 15464768 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose oxytocin (4.5 microm/min initially, increased by 4.5 microm/min every 30 min)
Number of subjects: 200
Study 15464768 — intervention group
Group type: COMPARATOR
Intervention: Low dose oxytocin (1.5 microm/min initially, increased by 1.5 microm/min every 30 min)
Number of subjects: 200
Study 11374116 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (5 g of Cr and 5 g maltodextrin four times a day for 5 days)
Number of subjects: 12
Study 11374116 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 12
Study 11374116 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) supplementation (5 g of maltodextrin four times a day for 5 days)
Number of subjects: 12
Study 9648966 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure level set to suppress flow limitation (PFL)
Number of subjects: 18
Study 9648966 — intervention group
Group type: COMPARATOR
Intervention: Positive pressure level set to eliminate only apnoea/hypopnoea and snoring (PAHS)
Number of subjects: 18
Study 9648966 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (PFL)
Number of subjects: 18
Study 9648966 — intervention group
Group type: COMPARATOR
Intervention: Group II (PAHS)
Number of subjects: 18
Study 9648966 — intervention group
Group type: EXPERIMENTAL
Intervention: Final maintenance of wakefulness test values
Number of subjects: 18
Study 7863015 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and high doses of alcohol
Number of subjects: 108
Study 7863015 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of diazepam
Number of subjects: 108
Study 7863015 — intervention group
Group type: COMPARATOR
Intervention: Baseline and treatment conditions
Number of subjects: 108
Study 2678856 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids
Number of subjects: 12
Study 2678856 — intervention group
Group type: COMPARATOR
Intervention: Non-steroid treatment
Number of subjects: 12
Study 949688 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate plus radiation
Number of subjects: 123
Study 949688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methotrexate plus radiation
Number of subjects: 123
Study 949688 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 123
Study 30382188 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/d)
Number of subjects: 34
Study 30382188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31079155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer drug-eluting stents (BP-DES)
Number of subjects: 95610
Study 31079155 — intervention group
Group type: COMPARATOR
Intervention: Permanent polymer drug-eluting stents (PP-DES)
Number of subjects: 95610
Study 29094074 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) program during CCRT
Number of subjects: 12
Study 25310347 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops four times daily for seven days
Number of subjects: 122
Study 25310347 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears four times daily for seven days
Number of subjects: 122
Study 25310347 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone 0.1%/povidone‐iodine 0.4% eye drops
Number of subjects: 122
Study 25310347 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 122
Study 24015254 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSS group
Number of subjects: 2
Study 24015254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 21565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Free oral hydration (Group A)
Number of subjects: 120
Study 21565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 10 mg of furosemide and infusion of 500 mL of saline solution starting 5 min after tracer injection (Group B)
Number of subjects: 120
Study 21565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydration with 500 mL of water (Group C)
Number of subjects: 120
Study 21565956 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 10 mg of furosemide and infusion of 250 mL of saline solution starting 30 min after (18)F‐FDG injection (Group D)
Number of subjects: 120
Study 18651888 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% xylocaine gel
Number of subjects: 90
Study 18651888 — intervention group
Group type: COMPARATOR
Intervention: KY jelly
Number of subjects: 90
Study 15939523 — intervention group
Group type: COMPARATOR
Intervention: 100 mJ irradiation
Number of subjects: 21
Study 15939523 — intervention group
Group type: COMPARATOR
Intervention: 200 mJ irradiation
Number of subjects: 21
Study 15939523 — intervention group
Group type: COMPARATOR
Intervention: 300 mJ irradiation
Number of subjects: 21
Study 12830441 — intervention group
Group type: EXPERIMENTAL
Intervention: Short daily HD
Number of subjects: 45
Study 12830441 — intervention group
Group type: EXPERIMENTAL
Intervention: Long nocturnal HD
Number of subjects: 45
Study 12830441 — intervention group
Group type: COMPARATOR
Intervention: Conventional thrice-weekly HD (Control)
Number of subjects: 45
Study 11296178 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily for five doses
Number of subjects: 36
Study 11296178 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg once daily for five doses
Number of subjects: 36
Study 11296178 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg q12h for nine doses
Number of subjects: 36
Study 8779455 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin, 4 g, given intravenously approximately 30 minutes before ERCP
Number of subjects: 551
Study 8779455 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given intravenously approximately 30 minutes before ERCP
Number of subjects: 551
Study 1580924 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (intervention)
Number of subjects: 0
Study 1580924 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (intervention)
Number of subjects: 0
Study 4076529 — intervention group
Group type: EXPERIMENTAL
Intervention: Clocapramine
Number of subjects: 26
Study 4076529 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 26
Study 29935582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 47
Study 29935582 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 47
Study 26042657 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation Manipulation Intervention (EMI)
Number of subjects: 90
Study 26042657 — intervention group
Group type: COMPARATOR
Intervention: Standard Medical Care
Number of subjects: 90
Study 26042657 — intervention group
Group type: COMPARATOR
Intervention: Attention Control Group
Number of subjects: 90
Study 24897168 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS
Number of subjects: 259
Study 24897168 — intervention group
Group type: EXPERIMENTAL
Intervention: FAPS
Number of subjects: 259
Study 24897168 — intervention group
Group type: EXPERIMENTAL
Intervention: FAP
Number of subjects: 259
Study 22187058 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercises (3-week rehabilitation program)
Number of subjects: 54
Study 20525705 — intervention group
Group type: EXPERIMENTAL
Intervention: torasemide 5 mg daily
Number of subjects: 30
Study 20525705 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 18827916 — intervention group
Group type: EXPERIMENTAL
Intervention: Zofenopril (n=719)
Number of subjects: 1418
Study 18827916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=699)
Number of subjects: 1418
Study 16238799 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized unmodified extract (Group A), maximum concentration of 308.5 mcg/mL, 11 injections total.
Number of subjects: 23
Study 16238799 — intervention group
Group type: COMPARATOR
Intervention: Standardized modified allergen extract (Group B), maximum concentration of 2400 mcg/mL, 11 injections total.
Number of subjects: 23
Study 11888774 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical systematic lymphadenectomy (LA)
Number of subjects: 94
Study 11888774 — intervention group
Group type: COMPARATOR
Intervention: Lymph node sampling (LS)
Number of subjects: 94
Study 10434810 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.2 mg kg‐1
Number of subjects: 60
Study 7892535 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg of Ringer solution (low dose crystalloid group)
Number of subjects: 36
Study 7892535 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml/kg of Ringer solution (high dose crystalloid group)
Number of subjects: 36
Study 7892535 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml/kg of Ringer solution with 10 ml/kg of hydroxi‐ethyl‐almidon solution (group C‐HEA)
Number of subjects: 36
Study 2198295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine treatment
Number of subjects: 8
Study 582393 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg viloxazin
Number of subjects: 5
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Coke (360 ml)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tab (360 ml)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant Maxwell House coffee (4.5 g)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant Kava coffee (4.5 g)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant Sanka coffee (4.5 g)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea (4.25 g)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (360 ml)
Number of subjects: 6
Study 6896312 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (360 ml)
Number of subjects: 6
Study 6896312 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 6
Study 30792154 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily
Number of subjects: 487
Study 30792154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 30792154 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (pooled analysis)
Number of subjects: 487
Study 30792154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pooled analysis)
Number of subjects: 487
Study 30565556 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 'A' (discontinued treatment)
Number of subjects: 155
Study 30565556 — intervention group
Group type: COMPARATOR
Intervention: Group 'NA' (completed treatment)
Number of subjects: 155
Study 26757749 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 83
Study 26757749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 24456145 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP-lowering therapy
Number of subjects: 71
Study 22232305 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose (0.2 mL/kg)
Number of subjects: 71
Study 22232305 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking (FT)
Number of subjects: 71
Study 22232305 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of FT and sucrose
Number of subjects: 71
Study 22232305 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 71
Study 21125792 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghuangbu-scaffold extract at 100 microg x mL(-1)
Number of subjects: 0
Study 21125792 — intervention group
Group type: EXPERIMENTAL
Intervention: Zein scaffold
Number of subjects: 0
Study 21125792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Shuanghuangbu-scaffold extract)
Number of subjects: 0
Study 17702997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethibond
Number of subjects: 9
Study 17702997 — intervention group
Group type: COMPARATOR
Intervention: Fiberwire
Number of subjects: 9
Study 15758128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 57
Study 15758128 — intervention group
Group type: COMPARATOR
Intervention: Bare stent
Number of subjects: 57
Study 12002757 — intervention group
Group type: EXPERIMENTAL
Intervention: Purine nucleoside analogues (PNA) including fludarabine (FAMP) and cladribine (2‐CdA)
Number of subjects: 0
Study 9579244 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic blood pressure cuffs
Number of subjects: 96
Study 9579244 — intervention group
Group type: COMPARATOR
Intervention: Manual blood pressure cuffs
Number of subjects: 96
Study 7714108 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-1 receptor antagonist (IL-1ra) alone (133 mg/h)
Number of subjects: 18
Study 7714108 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin alone (20 U/kg)
Number of subjects: 18
Study 7714108 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfusion of IL-1ra and endotoxin
Number of subjects: 18
Study 7714108 — intervention group
Group type: COMPARATOR
Intervention: Control study day
Number of subjects: 18
Study 2667400 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 83
Study 2667400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg)
Number of subjects: 83
Study 2667400 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.25 mg)
Number of subjects: 83
Study 2667400 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (5 mg)
Number of subjects: 83
Study 2667400 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (10 mg)
Number of subjects: 83
Study 2667400 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 2667400 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.125 mg)
Number of subjects: 83
Study 320866 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 1
Study 31373564 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Group (SG) using a wearable stoma simulator during sessions 2 and 3
Number of subjects: 46
Study 31373564 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) using the demonstration-return method during sessions 2 and 3
Number of subjects: 46
Study 31373564 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Group (SG)
Number of subjects: 46
Study 31373564 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 46
Study 28763808 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy
Number of subjects: 200
Study 28763808 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 200
Study 26319082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammaplasty group (MG)
Number of subjects: 80
Study 23782487 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) administration
Number of subjects: 78
Study 23782487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 21282282 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF→tamoxifen (3 cycles of CMF followed by tamoxifen for 57 months)
Number of subjects: 1669
Study 21282282 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone (for 5 years)
Number of subjects: 1669
Study 19106252 — intervention group
Group type: COMPARATOR
Intervention: Standardized functional physical and occupational therapies for 6 months (PT/OT group)
Number of subjects: 20
Study 19106252 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized functional physical and occupational therapies for 6 months plus multimuscle BTX‐A (BTX+ group)
Number of subjects: 20
Study 17200216 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (800 microg)
Number of subjects: 728
Study 17200216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 728
Study 17200216 — intervention group
Group type: COMPARATOR
Intervention: Folic acid vs Placebo
Number of subjects: 728
Study 17200216 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 728